In a recent talk at the 2016 ICare4Autism conference, leading autism researcher Eric Hollander presented his work on experimental therapeutics in autism spectrum disorder and Prader-Willi syndrome (PWS). Dr. Hollander is the recipient of an FPWR grant titled Oxytocin vs. placebo for the treatment of hyperphagia in Prader-Willi syndrome.
In this project, Dr. Hollander's group is conducting a treatment study of intranasal oxytocin vs. placebo in children and adolescents with both PWS and symptoms of ASD. They hypothesize that ocytocin will have a positive effect on eating, repetitive behaviors, and social cognition. The study is taking place in New York and is currently recruiting participants. More details including inclusion/exclusion critiera and contact information can be found here.
Dr. Hollander's talk at ICare4Autism was highlighted in YahooFinance.For updated information on PWS clinical trial opportunities and to sign up for a monthly PWS Clinical Trial Alert, visit the PWS Clinical Trials page.